
CLAIMS

1. Use of a compound having the formula



or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for treating complement 3 glomerulopathy in a human.

2. The use of claim 1, wherein the medicament slows the rate of decline in Estimated Glomerular Filtration Rate (eGFR) in a human suffering from C3 glomerulopathy.

3. The use of claim 1, wherein the medicament reduces glomerular inflammation in a human suffering from C3 glomerulopathy.

4. The use of claim 1, wherein the medicament reduces glomerular inflammatory macrophages in a human suffering from glomerulopathy.

5. The use of claim 1, wherein the medicament reduces proteinuria in a human suffering from C3 glomerulopathy.

6. The use of any one of claims 1 to 5 wherein the human suffers from progressive complement 3 glomerulonephritis.

7. The use of any one of claims 1 to 5 wherein the human suffers from recurrent complement 3 glomerulonephritis after a renal transplant.

8. The use of any one of claims 1 to 5 wherein the human suffers from dense deposit disease.

9. The use of any one of claims 1 to 5 wherein the complement 3 glomerulopathy is refractory to other treatment.

10. The use of any one of claims 1 to 9 wherein the human has refractory disease to immunosuppressive drugs.

11. The use of any one of claims 1 to 10 wherein the human has refractory disease to one or more of rituximab, cyclophosphamide, mycophenolate mofetil, tacrolimus, and steroids.

12. The use of any one of claims 1 to 11 wherein the medicament is to be administered twice daily.

13. The use of any one of claims 1 to 11 wherein the medicament is to be administered once a day.

14. The use of any one of claims 1 to 11 wherein the medicament is to be administration orally.

15. The use of any one of claims 1 to 11 wherein 30 mg of the compound is to be administered to the human twice daily.

16. The use of any one of claims 1 to 11, wherein the human has a Complement factor H related protein 5 (CFHR5) mutation.

17. The use of any one of claims 1 to 11 wherein the medicament is to be administered to the human for 12 weeks.